Prior to InteliCloud, Soniserved as vice president of sales, business development and customer servicesfor Fastsoft, an Internet accelerator appliance company, where he successfullyexecuted the go-to-market strategy, including short-term and long-termdevelopment goals. Soni has successfully sold to enterprise and service provider customersworldwide through direct and indirect (OEM and reseller) sales organizations,scaling revenues from zero to more than $200 million. "Sonny isa talented and seasoned professional who brings a wealth of knowledge andexperience that will help InteliCloud maximize its potential as a provider ofnext-generation networking solutions." A 20-year veteran of business development and sales, Soni has made a career ofcreating go-to-market strategies for successful networking equipment startups. "As the InteliCloud 360? hits the market, it is essential for us to have aseasoned and skillful leader on the business development front, and Sonny is theman for the job," said Ken Hubbard, president and CEO of InteliCloud. Hitendra Soni Will Oversee the Next-Generation Networking Provider`s Channel andIndustry PartnershipsNEWPORT BEACH, Calif.--(Business Wire)--InteliCloud, a developer and manufacturer of next-generation network equipment,today announced that Hitendra "Sonny" Soni has been named vice president ofbusiness development. Gray, 617-503-6632Chief Financial and Chief Operating Copyright Business Wire 2009. Curis disclaims any intention or obligation to update any ofthe forward-looking statements after the date of this press release whether as aresult of new information, future events or otherwise.Curis, Inc.Michael P.

Forexample, further preclinical testing of CUDC-305 may produce inconsistent,negative or inconclusive results which could cause the Company to delay orterminate its planned IND application for this drug candidate. These forward-looking statements are not guarantees offuture performance and involve risks, uncertainties, assumptions and otherfactors that may cause the actual results to be materially different from thoseindicated by such forward-looking statements including, among other things:* The Company may experience adverse results, delays and/or failures in itsinternal drug development programs, including without limitation unplanneddelays and/or failures in its ability to further advance its drug candidates,CUDC-101 and CUDC-305, and any other of its targeted cancer programs. For more information, visit Curis` websiteat Cautionary Statement: This press release contains forward-looking statementswithin the meaning of the Private Securities Litigation Reform Act of 1995,including without limitation: statements regarding management`s expectation thatthe Company may enter into a collaboration agreement for CUDC-305 in 2009 andits expectations regarding the potential safety, efficacy and broad therapeuticbenefits ofthis compound in multiple cancer indications.Forward-lookingstatements used in this press release may contain the words "believes","expects", "anticipates", "plans", "seeks", "estimates", "will", "may" orsimilar expressions. In expanding its drug development efforts in the field of cancerthrough its targeted cancer programs, Curis is building upon its previousexperiences in targeting signaling pathways for the development of nextgeneration targeted cancer therapies. About Curis, Inc.Curis is a drug development company that is committed to leveraging itsinnovative signaling pathway drug technologies to seek to create new medicinesfor cancer. Inhibitors of Hsp90 activitymay be of therapeutic value if they can prevent Hsp90 proteins from protectingthe particular client proteins involved in cancer and allow them to be degraded,thereby inducing cancer cell death.

Hsp90, inparticular, has become an attractive therapeutic target for the treatment ofcancer because a majority of its client proteins are involved in cellularsignaling transduction and have been identified as potential contributors tovarious aspects of cancer cell growth and survival. About Hsp90Hsp90 is a member of a class of proteins called molecular chaperones that play afundamental role in the folding, stabilization and degradation of other cellularproteins, or clients, under normal or stressful conditions. The Company intends to continue to studyCUDC-305 in preclinical studies and is optimistic that its findings may serve asthe basis for an IND filing to commence a clinical trial of the drug under FDAguidelines in mid-2009. With respect to safety, CUDC-305demonstrated specificity for tumor cells over normal cells and was consistentlywell tolerated in animal models. The compound displayed significant tumor retention of 20.5hours and an oral bioavailability of 96%. In addition, the presentation includesdata indicating that the potency of the compound was unaffected by theexpression level of a key mediator of drug resistance, the multi-drug resistanceprotein 1 (MDR-1). The poster also provided data demonstrating CUDC-305`sfavorable pharmacological profile in vitro, including a higher binding affinityto cancer chaperone complex and prolonged biological effects tocancer-associated Hsp90 client proteins.

The poster highlighted datademonstrating that CUDC-305 induced tumor regression in a subcutaneous xenograftmodel for glioblastoma. The second presentation, a poster entitled "A Novel Tumor-specific Hsp90Inhibitor with Long Lasting Biological Activity," reported that CUDC-305exhibited significant potency against a broad range of solid and hematologicaltumor cell lines in anti-proliferation assays. Overall, the compound exhibited a favorable safetyprofile in these studies. CUDC-305 also demonstrated efficacy inpreclinical hematological cancer models, inducing complete regression in anacute myloid leukemia model. The compound exhibitedsignificant brain penetrability and also significantly enhanced survival inpreclinical intracranial tumor models. In addition toNSCLC, CUDC-305 demonstrated tumor regression in breast, colorectal andglioblastoma preclinical cancer models as a single agent or in combination withother targeted drugs or standard chemotherapeutics.